IL18 and metabolic syndrome: In prostate stromal cells, no statistically significant differences were found in the overall percentage of IL-18 (+) cells, IL-18 (−) cells, and in any of the levels of intensity of immunohistochemical expression between the patients without MetS and with MetS (Supplementary Table 2, Figure 4C).